Just this morning, exciting news was published; pharmaceutical company Eli Lily reached a $2.75 billion deal with Hong Kong based Insilico Medicine. The deal was established around the premise that Eli Lily would produce drugs, developed using Insilico Medicine's artificial intelligence technologies, to the global market.
Eli Lily is a pharmaceutical company that engages in research and investments in U.S. manufacturing, as well as producing novel medicines. More specifically, the company is focused on developing treatments for diabetes, obesity, immunology, and oncology. It is widely recognized for the development of Mounjaro and Zepbound for weight loss and type two diabetes.
On the other hand, Insilico Medicine is a company labeled on its website to be a "generative AI software for drug discovery, scientific research and sustainability." Moreover, its mission is to transform "drug discovery and development with generative artificial intelligence," a tool which is rapidly rising in popularity.
It is becoming increasingly normalized to utilize artificial intelligence to accelerate drug research and development. Under this new agreement, Reuters states that "Lilly will receive an exclusive license to develop, manufacture and commercialize preclinical oral drug candidates by Insilico Medicine for selected disease areas." Vice President of Molecule Discovery at Lily named "Insilico’s AI-enabled discovery '“a powerful complement”' to Lilly’s clinical development."
How is artificial intelligence used to enhance and accelerate drug development and production? A mareana article written in 2024 states that artificial intelligence can be used to "analyze vast amounts of data to identify potential drug candidates, saving scientists precious time in the initial research phase." Another advantage of using AI in drug is that it can "predict the properties and behavior of these compounds, helping researchers select the most promising candidates for further testing." Third, newly "AI-powered robotics and automation are optimizing drug production, improving efficiency, and reducing errors. By leveraging AI, pharmaceutical companies can speed up the manufacturing process while maintaining quality and safety standards."
The mareana article ends with concluding that "as AI continues to evolve, its impact on the pharmaceutical industry is likely to be transformative." Importantly, this article was written two years ago, revealing it did accurately predict the use of AI to change the pharmaceutical industry. Yet this transformation has only continued and accelerated since then. How do you think this transformation will continue?
Add comment
Comments